In most cases of acromegaly, this excessive growth hormone production stems from a noncancerous tumor in the pituitary gland. However, in rarer instances, the disease can be triggered by tumors ...

The novel consensus statement highlights current analytical pitfalls and the need to optimize disease control in acromegaly. Acromegaly is a serious endocrine disease associated with increased ...

Endocrinology specialist Dr Preethi Dissanayake discusses this uncommon presentation, in the latest in our series on ...

Acromegaly is due to hypersecretion of growth ... Medical treatment of the disease is usually with somatostatin analogs. An open, prospective, single-center study by Maiza et al.

Acromegaly is a life-shortening disease where much of the morbidity is caused by insulin resistance, lipotoxicity, and cardiovascular events. Current therapies for acromegaly are associated with ...

Marea’s Phase IIa study enrolled patients with hypertriglyceridemia—too much fat in the blood. The latest results showed the ...

Somatostatin analogues are clinically used for the treatment of acromegaly and have the benefit of both reduction of tumor size and hormonal control of this disease. Because pituitary corticotroph ...

Crinetics Pharmaceuticals is set for a fall 2025 launch of paltusotine, with strong Wall Street support despite being ...

Paltusotine hydrochloride is under clinical development by Crinetics Pharmaceuticals and currently in Pre-Registration for Acromegaly.